These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
163 related articles for article (PubMed ID: 10547426)
1. Protection of mice against P. aeruginosa infections by large-scale affinity-purified human IgG specific to P. aeruginosa outer membrane proteins. Lee NG; Jung SB; Ahn BY; Kim YG; Lee Y; Jeon YJ; Park WJ Vaccine; 1999 Nov; 18(7-8):665-74. PubMed ID: 10547426 [TBL] [Abstract][Full Text] [Related]
2. Human anti-Pseudomonas aeruginosa outer membrane proteins IgG cross-protective against infection with heterologous immunotype strains of P. aeruginosa. Lee NG; Ahn BY; Jung SB; Kim YG; Lee Y; Kim HS; Park WJ FEMS Immunol Med Microbiol; 1999 Sep; 25(4):339-47. PubMed ID: 10497864 [TBL] [Abstract][Full Text] [Related]
3. Immunization of burn-patients with a Pseudomonas aeruginosa outer membrane protein vaccine elicits antibodies with protective efficacy. Lee NG; Jung SB; Ahn BY; Kim YH; Kim JJ; Kim DK; Kim IS; Yoon SM; Nam SW; Kim HS; Park WJ Vaccine; 2000 Mar; 18(18):1952-61. PubMed ID: 10699346 [TBL] [Abstract][Full Text] [Related]
4. A live-attenuated Pseudomonas aeruginosa vaccine elicits outer membrane protein-specific active and passive protection against corneal infection. Zaidi TS; Priebe GP; Pier GB Infect Immun; 2006 Feb; 74(2):975-83. PubMed ID: 16428743 [TBL] [Abstract][Full Text] [Related]
5. Protective effects of affinity-purified antibody and truncated vaccines against Pseudomonas aeruginosa V-antigen in neutropenic mice. Moriyama K; Wiener-Kronish JP; Sawa T Microbiol Immunol; 2009 Nov; 53(11):587-94. PubMed ID: 19903258 [TBL] [Abstract][Full Text] [Related]
6. The prophylactic effects of human IgG derived from sera containing high anti-PcrV titers against pneumonia-causing Pseudomonas aeruginosa. Kinoshita M; Kato H; Yasumoto H; Shimizu M; Hamaoka S; Naito Y; Akiyama K; Moriyama K; Sawa T Hum Vaccin Immunother; 2016 Nov; 12(11):2833-2846. PubMed ID: 27454613 [TBL] [Abstract][Full Text] [Related]
8. [Preparation of Pseudomonas aeruginosa recombinant outer-membrane protein F and the study of its antigenic properties]. Kaloshin AA; Zlygostev SA; Toropchina IuN; Kurbatova EA; Zverev VV; Mikhaĭlova NA Zh Mikrobiol Epidemiol Immunobiol; 2005; (5):50-3. PubMed ID: 16279535 [TBL] [Abstract][Full Text] [Related]
9. Immunization with the ferric iron-binding periplasmic protein HitA provides protection against Pseudomonas aeruginosa in the murine infection model. Elhosary MA; Bahey-El-Din M; AbdelBary A; El Guink N; Aboushleib HM Microb Pathog; 2019 Jun; 131():181-185. PubMed ID: 30978430 [TBL] [Abstract][Full Text] [Related]
10. Human immune response to a Pseudomonas aeruginosa outer membrane protein vaccine. Jang IJ; Kim IS; Park WJ; Yoo KS; Yim DS; Kim HK; Shin SG; Chang WH; Lee NG; Jung SB; Ahn DH; Cho YJ; Ahn BY; Lee Y; Kim YG; Nam SW; Kim HS Vaccine; 1999 Jan; 17(2):158-68. PubMed ID: 9987150 [TBL] [Abstract][Full Text] [Related]
11. Prophylactic and therapeutic efficacy of immunoglobulin G antibodies to Pseudomonas aeruginosa lipopolysaccharide against murine experimental corneal infection. Preston MJ; Gerçeker AA; Koles NL; Pollack M; Pier GB Invest Ophthalmol Vis Sci; 1997 Jun; 38(7):1418-25. PubMed ID: 9191605 [TBL] [Abstract][Full Text] [Related]
12. Outer membrane protein F (porin) preparation of Pseudomonas aeruginosa as a protective vaccine against heterologous immunotype strains in a burned mouse model. Matthews-Greer JM; Gilleland HE J Infect Dis; 1987 Jun; 155(6):1282-91. PubMed ID: 3033095 [TBL] [Abstract][Full Text] [Related]
13. Evaluation of protective mAbs against Pseudomonas aeruginosa outer membrane protein I by C1q binding assay. Eckhardt A; Heiss MM; Ehret W; Permanetter W; Duchêne M; Domdey H; von Specht BU Zentralbl Bakteriol; 1991 Apr; 275(1):100-11. PubMed ID: 1930557 [TBL] [Abstract][Full Text] [Related]
14. Antibody responses induced by long-term vaccination with an octovalent conjugate Pseudomonas aeruginosa vaccine in children with cystic fibrosis. Zuercher AW; Horn MP; Que JU; Ruedeberg A; Schoeni MH; Schaad UB; Marcus P; Lang AB FEMS Immunol Med Microbiol; 2006 Jul; 47(2):302-8. PubMed ID: 16831219 [TBL] [Abstract][Full Text] [Related]
15. Protective efficacy of Pseudomonas aeruginosa type-A flagellin in the murine burn wound model of infection. Faezi S; Safarloo M; Amirmozafari N; Nikokar I; Siadat SD; Holder IA; Mahdavi M APMIS; 2014 Feb; 122(2):115-27. PubMed ID: 23758581 [TBL] [Abstract][Full Text] [Related]
16. Outer membrane protein F preparation of Pseudomonas aeruginosa as a vaccine against chronic pulmonary infection with heterologous immunotype strains in a rat model. Gilleland HE; Gilleland LB; Matthews-Greer JM Infect Immun; 1988 May; 56(5):1017-22. PubMed ID: 2833440 [TBL] [Abstract][Full Text] [Related]
17. [Cell-free Pseudomonas vaccine. IV. Laboratory trials of the effectiveness of experimental Pseudomonas vaccines]. Stanislavskiĭ ES; Joó I; Bulk VF; Zhvanetskaia MI; Mashilova GM Zh Mikrobiol Epidemiol Immunobiol; 1982 Oct; (10):25-9. PubMed ID: 6817559 [TBL] [Abstract][Full Text] [Related]